Accendra Health Stock-Based Compensation Growth & History (ACH)
Accendra Health's stock-based compensation was $12.9M for fiscal 2025.
View full Accendra Health company overviewAccendra Health annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.9M | −$3.8M | −22.63% |
| 2024 | 2024-12-31 | $16.6M | $2.2M | +15.58% |
| 2023 | 2023-12-31 | $14.4M | −$6.6M | −31.43% |
| 2022 | 2022-12-31 | $21.0M | −$4.0M | −16.08% |
| 2021 | 2021-12-31 | $25.0M | $5.0M | +25.02% |
| 2020 | 2020-12-31 | $20.0M | $4.2M | +26.62% |
| 2019 | 2019-12-31 | $15.8M | −$573,000 | −3.50% |
| 2018 | 2018-12-31 | $16.4M | $4.5M | +37.49% |
| 2017 | 2017-12-31 | $11.9M | −$131,000 | −1.09% |
| 2016 | 2016-12-31 | $12.0M | $736,000 | +6.51% |
| 2015 | 2015-12-31 | $11.3M | $3.1M | +37.76% |
| 2014 | 2014-12-31 | $8.2M | $1.8M | +28.62% |
| 2013 | 2013-12-31 | $6.4M | $684,000 | +12.01% |
| 2012 | 2012-12-31 | $5.7M | $23,000 | +0.41% |
| 2011 | 2011-12-31 | $5.7M | −$684,000 | −10.76% |
| 2010 | 2010-12-31 | $6.4M | −$677,000 | −9.62% |
| 2009 | 2009-12-31 | $7.0M | −$528,000 | −6.98% |
| 2008 | 2008-12-31 | $7.6M | — | — |
Accendra Health quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.0M | −$868,000 | −17.82% |
| Q1 2026 | 2026-03-31 | $3.1M | −$1.3M | −30.11% |
| Q4 2025 | 2025-12-31 | −$4.5M | — | — |
| Q3 2025 | 2025-09-30 | $8.0M | $2.4M | +41.50% |
| Q2 2025 | 2025-06-30 | $4.9M | −$1.9M | −27.66% |
| Q1 2025 | 2025-03-31 | $4.4M | −$2.4M | −35.61% |
| Q3 2024 | 2024-09-30 | $5.7M | −$62,000 | −1.08% |
| Q2 2024 | 2024-06-30 | $6.7M | $1.5M | +29.22% |
| Q1 2024 | 2024-03-31 | $6.9M | $403,000 | +6.24% |
| Q3 2023 | 2023-09-30 | $5.7M | $1.2M | +26.06% |
| Q2 2023 | 2023-06-30 | $5.2M | −$595,000 | −10.25% |
| Q1 2023 | 2023-03-31 | $6.5M | $1.1M | +19.62% |
| Q4 2022 | 2022-12-31 | $5.2M | −$710,000 | −11.96% |
| Q3 2022 | 2022-09-30 | $4.6M | −$1.5M | −24.56% |
| Q2 2022 | 2022-06-30 | $5.8M | −$2.1M | −26.10% |
| Q1 2022 | 2022-03-31 | $5.4M | $221,000 | +4.26% |
| Q4 2021 | 2021-12-31 | $5.9M | $1.2M | +25.41% |
| Q3 2021 | 2021-09-30 | $6.0M | −$1.4M | −19.07% |
| Q2 2021 | 2021-06-30 | $7.9M | $4.0M | +102.89% |
| Q1 2021 | 2021-03-31 | $5.2M | $1.2M | +31.49% |
| Q4 2020 | 2020-12-31 | $4.7M | $989,000 | +26.40% |
| Q3 2020 | 2020-09-30 | $7.5M | $3.5M | +88.22% |
| Q2 2020 | 2020-06-30 | $3.9M | $285,000 | +7.94% |
| Q1 2020 | 2020-03-31 | $3.9M | −$564,000 | −12.52% |
| Q4 2019 | 2019-12-31 | $3.7M | −$2.1M | −36.26% |
| Q3 2019 | 2019-09-30 | $4.0M | −$395,000 | −9.06% |
| Q2 2019 | 2019-06-30 | $3.6M | $483,000 | +15.56% |
| Q1 2019 | 2019-03-31 | $4.5M | $1.5M | +48.43% |
| Q4 2018 | 2018-12-31 | $5.9M | $2.6M | +77.07% |
| Q3 2018 | 2018-09-30 | $4.4M | $1.4M | +46.62% |
| Q2 2018 | 2018-06-30 | $3.1M | −$3,000 | −0.10% |
| Q1 2018 | 2018-03-31 | $3.0M | $524,000 | +20.87% |
| Q4 2017 | 2017-12-31 | $3.3M | $211,000 | +6.79% |
| Q3 2017 | 2017-09-30 | $3.0M | $8,000 | +0.27% |
| Q2 2017 | 2017-06-30 | $3.1M | −$258,000 | −7.66% |
| Q1 2017 | 2017-03-31 | $2.5M | −$92,000 | −3.53% |
| Q4 2016 | 2016-12-31 | $3.1M | −$587,000 | −15.89% |
| Q3 2016 | 2016-09-30 | $3.0M | $402,000 | +15.68% |
| Q2 2016 | 2016-06-30 | $3.4M | $915,000 | +37.33% |
| Q1 2016 | 2016-03-31 | $2.6M | $6,000 | +0.23% |
| Q4 2015 | 2015-12-31 | $3.7M | $1.6M | +78.42% |
| Q3 2015 | 2015-09-30 | $2.6M | $617,000 | +31.71% |
| Q2 2015 | 2015-06-30 | $2.5M | $903,000 | +58.33% |
| Q1 2015 | 2015-03-31 | $2.6M | −$45,000 | −1.70% |
| Q4 2014 | 2014-12-31 | $2.1M | $852,000 | +69.89% |
| Q3 2014 | 2014-09-30 | $1.9M | $233,000 | +13.60% |
| Q2 2014 | 2014-06-30 | $1.5M | $9,000 | +0.58% |
| Q1 2014 | 2014-03-31 | $2.6M | $732,000 | +38.32% |
| Q4 2013 | 2013-12-31 | $1.2M | $366,000 | +42.91% |
| Q3 2013 | 2013-09-30 | $1.7M | $995,000 | +138.58% |
| Q2 2013 | 2013-06-30 | $1.5M | −$202,000 | −11.60% |
| Q1 2013 | 2013-03-31 | $1.9M | −$475,000 | −19.92% |
| Q4 2012 | 2012-12-31 | $853,000 | −$486,000 | −36.30% |
| Q3 2012 | 2012-09-30 | $718,000 | −$36,000 | −4.77% |
| Q2 2012 | 2012-06-30 | $1.7M | $1.2M | +210.89% |
| Q1 2012 | 2012-03-31 | $2.4M | −$636,000 | −21.05% |
| Q4 2011 | 2011-12-31 | $1.3M | $433,000 | +47.79% |
| Q3 2011 | 2011-09-30 | $754,000 | −$65,000 | −7.94% |
| Q2 2011 | 2011-06-30 | $560,000 | −$1.1M | −66.43% |
| Q1 2011 | 2011-03-31 | $3.0M | $56,000 | +1.89% |
| Q4 2010 | 2010-12-31 | $906,000 | — | — |
| Q3 2010 | 2010-09-30 | $819,000 | −$882,000 | −51.85% |
| Q2 2010 | 2010-06-30 | $1.7M | — | — |
| Q1 2010 | 2010-03-31 | $3.0M | — | — |
| Q3 2009 | 2009-09-30 | $1.7M | — | — |
Accendra Health stock-based compensation trends
Over the last five fiscal years, Accendra Health's stock-based compensation decreased from $20.0M to $12.9M, a change of −$7.1M. The latest reported quarter, Q2 2026, shows $4.0M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Accendra Health source filings ↗